Evaxion reports durable three-year EVX-01 melanoma vaccine results

Evaxion reported on October 23, 2026 that patients in its phase 2 advanced-melanoma study retained their clinical responses after three years, with no tumor progression during the extension period when EVX-01 was used alone. The vaccine generated tumor-specific immune responses against 89% of its personalized antigen targets, and the company said an immune response occurred in all patients. Earlier two-year results showed objective responses in 75% of patients, while 25% achieved a complete response; the updated findings are scheduled for presentation at ESMO 2026 on October 24, 2026.

The report extends the observed durability of Evaxion's lead clinical program and provides additional clinical and immune-response data ahead of the ESMO presentation. Evaxion's CSO and COO said the findings support EVX-01 and the company's AI-Immunology platform, while the data remain from a phase 2 study rather than a regulatory approval.

  • 1Six out of 12 responders entered a one-year extension in which EVX-01 was administered as a stand-alone treatment.
  • 2The company reported immune responses in all patients, with 89% of personalized vaccine antigen targets producing a tumor-specific immune response.
  • 3The earlier two-year results recorded a 75% objective response rate, with 25% of patients achieving a complete response.
  • 4The ESMO poster is scheduled for October 24, 2026, and Evaxion plans a follow-up webinar on October 29, 2026.
  • 5At the two-year follow-up, 86% of vaccine neoantigens generated potent specific T-cell responses, rising to 89% after analysis of additional extension-phase samples.

Sources